Antithrombotic therapy in peripheral artery disease

T. Raymond Foley; Stephen W. Waldo; Ehrin J. Armstrong

doi:10.1177/1358863X15622987

Antithrombotic therapy in peripheral artery disease

T. Raymond Foley, Stephen W. Waldo, Ehrin J. Armstrong

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.

Original language	English (US)
Pages (from-to)	156-169
Number of pages	14
Journal	Vascular Medicine (United Kingdom)
Volume	21
Issue number	2
DOIs	https://doi.org/10.1177/1358863X15622987
State	Published - Apr 1 2016
Externally published	Yes

Keywords

anticoagulants
arterial occlusive diseases
critical limb ischemia
intermittent claudication
peripheral artery disease
platelet aggregation inhibitors

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1177/1358863X15622987

Fingerprint Dive into the research topics of 'Antithrombotic therapy in peripheral artery disease'. Together they form a unique fingerprint.

Cite this

@article{8021fca60dc54df7a2b7dc4ed32a0f2b,

title = "Antithrombotic therapy in peripheral artery disease",

abstract = "Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.",

keywords = "anticoagulants, arterial occlusive diseases, critical limb ischemia, intermittent claudication, peripheral artery disease, platelet aggregation inhibitors",

author = "Foley, {T. Raymond} and Waldo, {Stephen W.} and Armstrong, {Ehrin J.}",

year = "2016",

month = apr,

day = "1",

doi = "10.1177/1358863X15622987",

language = "English (US)",

volume = "21",

pages = "156--169",

journal = "Vascular Medicine (United Kingdom)",

issn = "1358-863X",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Antithrombotic therapy in peripheral artery disease

AU - Foley, T. Raymond

AU - Waldo, Stephen W.

AU - Armstrong, Ehrin J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.

AB - Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.

KW - anticoagulants

KW - arterial occlusive diseases

KW - critical limb ischemia

KW - intermittent claudication

KW - peripheral artery disease

KW - platelet aggregation inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84961238168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961238168&partnerID=8YFLogxK

U2 - 10.1177/1358863X15622987

DO - 10.1177/1358863X15622987

M3 - Review article

C2 - 26823456

AN - SCOPUS:84961238168

VL - 21

SP - 156

EP - 169

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

SN - 1358-863X

IS - 2

ER -